LONDON, May 14, 2025--(BUSINESS WIRE)--Kesmalea Therapeutics, a biopharmaceutical company developing a pipeline of novel therapeutics founded on the ability to transform large heterobifunctional ...
With just 17 games played with the Hershey Bears in 2012-13, Matt Clackson is on pace to play the fewest games of his five-year pro career. In fact, he is also on pace to play fewer games than any of ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Tim Clackson is president of R&D and chief scientific ...
The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Alberta Justice ...
What does this Advisor Specialize in? Find a financial advisor who specializes in the area of expertise you require. It's important to find an advisor who can help you approach your personal and ...
Dr. Clackson is former CEO of IDRx, acquired by GSK in 2025 for up to $1.15 billion Kesmalea's SELFTAC platform is designed to solve the 'size problem' of large, bifunctional protein degraders by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results